ASH Annual Meeting and Exposition
ASH Annual Meeting and Exposition
December 12, 2019
1 min read

Anti-PD-1 therapy after CAR T-cell therapy shows efficacy in Hodgkin lymphoma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Timothy Voorhees

ORLANDO — Researchers demonstrated the clinical efficacy of anti-PD-1 mAb therapy following treatment with chimeric receptor modified T cells targeting the CD30 molecule, known as CD30.CAR-T, in a small sample of patients with relapsed/refractory Hodgkin lymphoma, according to a study presented at ASH Annual Meeting and Exposition.

In a retrospective cohort review, Timothy Voorhees, MD, clinical fellow, division of hematology/oncology, University of North Carolina School of Medicine, and colleagues examined the safety and efficacy of anti-PD-1 mAb therapy (CPI) post CD30.CAR-T cell therapy in five patients with relapsed/refractory Hodgkin lymphoma who later received CPI to treat relapsed disease after CD30.CAR-T progression. They determined clinical responses during the follow-up period.

“While the majority of patients with relapse had prior anti-PD-1 exposure, rechallenging with anti-PD-1 therapy was attempted,” Voorhees told HemOnc Today.

Voorhees reported that all patients treated with anti-PD-1 therapy following CD30 directed CAR T-cell therapy exhibited clinical response. Four patients achieved a complete response and one achieved a partial response.

Clinical responses seemed to be improved after CD30 directed CAR T-cell therapy compared with before in patients with prior anti-PD-1 exposure, according to Voorhees.

All five patients were heavily pre-treated with a median of eight therapies prior to CD30.CAR-T, according to the abstract. After CD30.CAR-T infusion, all patients subsequently developed progressive disease. The median time from CD30.CAR-T to CPI was 132 days.

Data showed the median duration of response was 212 days, with ongoing response observed in three patients. One patient developed neuropathy, another developed grade 3 colitis, and a third developed pneumonitis; however, all patients were still alive at last follow up with a median OS of 2.44 years from first CD30.CAR-T cell therapy, per the abstract.

“While these results are encouraging, prospective confirmation of both clinical response and immunophenotype characterization during treatment with anti-PD-1 therapy after CD30 directed CAR T-cell therapy are needed to confirm these findings,” Voorhees told HemOnc Today. “Plans for this treatment are being discussed at our institution.” – by Savannah Demko


Voorhees TJ, et al. Abstract 3233. Presented at: ASH Annual Meeting and Exposition; December 7-10, 2019; Orlando, Florida.

Disclosures: Voorhees reports no relevant financial disclosures.